Mein Warenkorb

CXCR4

CXCR4 Molekülinformation

Englischer NameC-X-C motif chemokine receptor 4Anzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel30Target-AliasNPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine (C-X-C Motif) Receptor 4,CD184 Antigen,C-X-C Motif Chemokine Receptor 4,Lipopolysaccharide-Associated Protein 3
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameC-X-C motif chemokine receptor 4
Target-AliasNPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine (C-X-C Motif) Receptor 4,CD184 Antigen,C-X-C Motif Chemokine Receptor 4,Lipopolysaccharide-Associated Protein 3
Anzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel30
Höchste Forschungs- und EntwicklungsphaseApproved

CXCR4 Produktliste

  • Attribut

    Protein (3)

  • Produktbibliothek

    Online (3)

  • Spezies

    Human (3)

  • Etikett

    Fc Tag (1)- (1)His Tag & Flag Tag (1)

  • Marker

    Unconjugated (3)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
CX4-H5219
Human
HEK293
Human CXCR4 / CD184 Full Length Protein (VLP) In den Warenkorb legen
CX4-H5269
Human
HEK293
Human CXCR4 / CD184 Protein, Fc Tag
In den Warenkorb legen
CX4-H52D3
Human
HEK293
Human CXCR4 Full Length Protein, Flag,His Tag (Detergent)
In den Warenkorb legen
Gesamtmenge3
  • 1

CXCR4 Molekülhintergrund

C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

CXCR4 Molekülalias

CXCR4,CD184,Fusin,D2S201E,FB22,HM89,HSY3RR,LAP3,LCR1,LESTR,NPY3R,NPYR,NPYRL,NPYY3R,WHIM

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
CXCR4 mAb - 01LeadMonoclonalHumanized MouseHematological Malignancy,AutoImmunityBlood tumor,Solid tumor
DLL3 mAb - 01LeadMonoclonalFull HumanSolid TumorSmall cell lung cancer

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
90Y-PentixatherPhase 2 ClinicalTechnical University Of Munich, University Of WurzburgCentral Nervous System Lymphoma; Multiple Myeloma
Details
177Lu-PentixatherPhase 2 ClinicalNantes University Hospital, Technical University Of Munich, University Of WurzburgLeukemia; Multiple Myeloma
Details
Burixafor HydrobromideTG-0054; GP 01; GPC-100; TG-3000Phase 2 ClinicalTaiGen Biotechnology Co LtdHematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Prostatic Neoplasms
Details
RAP-103RAP-160; RAP-701; RAP-164; RAP-310; RAP-163; RAP-103Phase 2 ClinicalRapid PharmaceuticalsAlzheimer Disease; Hepatitis B; Neuralgia; Ovarian Neoplasms; Prostatic Neoplasms; Psoriasis
Details
PTX-9908PTX-9908Phase 2 ClinicalPertinax TherapeuticsCarcinoma, Hepatocellular
Details
68Ga-pentixaforCXCR4-PET; 68Ga-PTF; [68Ga]Ga-PTF; CXCR4; gallium (68Ga) boclatixafortide; gallium (⁶⁸Ga) boclatixafortide; GALLIUM BOCLATIXAFORTIDE GA-68Phase 2 ClinicalScintomics, University Of MunichCentral Nervous System Lymphoma; Cushing Syndrome; Graft vs Host Disease; Hyperaldosteronism; Lymphoma, B-Cell, Marginal Zone; Neuroendocrine Tumors; Sarcoidosis
Details
99mTc-CXCR499mTc-CXCR4Phase 2 ClinicalShiraz University Of Medical SciencesGlioblastoma
Details
18F-BL4018F-BL40Phase 2 ClinicalBritish Columbia Cancer AgencyLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details
Al18F-NOTA-PentixaforPhase 2 ClinicalPeking Union Medical College HospitalHyperaldosteronism
Details
Ga-68-CXCR4Ga-68-CXCR4Phase 2 ClinicalKoo Foundation Sun Yat-Sen Cancer CenterLymphoma, B-Cell
Details
Plerixafor/Tacrolimus HydrateMRG-001(MedRegen); AMD3100+FK506Phase 2 ClinicalMedRegen LLCAbdominal Injuries; Amyotrophic Lateral Sclerosis; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Hepatitis, Alcoholic; Motor Neuron Disease; Respiratory Distress Syndrome, Adult; Respiratory Insufficiency; Respiratory Tract Diseases; Wounds and Injuries
Details
NRP-2945NRP-2945; NNZ-4945Phase 2 ClinicalCalzada Ltd, Neuren Pharmaceuticals LtdAmyotrophic Lateral Sclerosis; Angelman Syndrome; Epilepsy, Absence; Epilepsy, Temporal Lobe; Lennox Gastaut Syndrome; Rett Syndrome
Details
GPC-201GPC-201Phase 2 ClinicalGPCR Therapeutics USA IncHematopoietic stem cell transplantation (HSCT)
Details
4-P-0214P021; 4-P-021Phase 2 Clinical4P-Pharma Ltd, Institut Pasteur De Lille, University of BordeauxCoronavirus Disease 2019 (COVID-19)
Details
CGT-1881CGT1881; CGT-1881Phase 2 ClinicalCgenetech(Suzhou China) Co LtdHematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Lymphoma, Non-Hodgkin; Multiple Myeloma
Details
AGT 103-TAGT 103-TPhase 1 ClinicalAmerican Gene Technologies International IncHIV Infections
Details
BalixafortidePOL-6326Phase 1 ClinicalPolyphor LtdBreast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
JVS-100JVS-100; SRX-100; ACRX-100; GP-51801; GP51801Phase 1 ClinicalCleveland ClinicHeart Failure; Ischemia; Peripheral Arterial Disease; Surgical Wound
Details
CXCR4 modulator(Ligand/Upsher Smith)Phase 1 ClinicalLigand Pharmaceuticals IncNeoplasms
Details
CXCR4 CCR9 CAR-T therapy (The First Affiliated Hospital of Soochow University)Phase 1 ClinicalThe First Affiliated Hospital Of Soochow UniversityLeukemia
Details
GP-8012GP-8012; GP8012Phase 1 ClinicalNanjing Gritpharma Co LtdIschemia; Peripheral Arterial Disease
Details
68Ga-JH1268Ga-JH12Phase 1 ClinicalBivision Pharmaceuticals IncNeoplasms
Details
vMIP (Guangzhou Hongrun Biotech)Phase 1 ClinicalGuangzhou Hongrun Biotechnology Co LtdPneumonia
Details
203-Lead PentixatherPhase 1 ClinicalHolden Comprehensive Cancer Center, National Cancer Institute, National Institutes Of HealthLung Neoplasms; Small Cell Lung Carcinoma
Details
212-Lead PentixatherPhase 1 ClinicalHolden Comprehensive Cancer Center, National Cancer Institute, National Institutes Of HealthLung Neoplasms; Small Cell Lung Carcinoma
Details
68Ga-Pentixather68Ga-PentixatherPhase 1 ClinicalPeking Union Medical College HospitalMultiple Myeloma; Small Cell Lung Carcinoma
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
AD-214AD-214Phase 1 ClinicalAdalta LtdLung Diseases, Interstitial
Details
[18F]AlF-NOTA-pentixather18F-AlF-NOTA-pentixatherClinicalSichuan Provincial People'S HospitalAdenoma
Details
X-4136X-4136ClinicalX4 Pharmaceuticals IncLymphoma, B-Cell; Melanoma; Uterine Cervical Neoplasms
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
PlerixaforSDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100ApprovedGenzyme CorpMozobil, Mobozil, 释倍灵United StatesLymphoma, Non-Hodgkin; Multiple MyelomaGenzyme Corp2008-12-15Adenocarcinoma; Agranulocytosis; Anemia, Sickle Cell; Bone metastases; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Cystic Fibrosis; Fanconi Anemia; Granulomatous Disease, Chronic; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Leukopenia; Lymphoma; Lymphoma, Non-Hodgkin; Lymphopenia; Multiple Myeloma; Myelodysplastic Syndromes; Neutropenia; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Graft Dysfunction; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Rejection of organ transplantation; Respiratory Distress Syndrome, Adult; Warts; WHIM syndrome; Wiskott-Aldrich Syndrome
Details
MavorixaforX4P-001-LD; ABSK-081; X4P-001-IO; AMD-11070; AMD-070; X4P-001; X4P-001-RDApprovedGenzyme CorpXolremdi, XOLREMDIUnited StatesWHIM syndromeX4 Pharmaceuticals Inc2024-04-26Carcinoma, Renal Cell; Hepatic Insufficiency; HIV Infections; Melanoma; Neutropenia; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; WHIM syndrome
Details
Motixafortide4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168; 4F-benzoyl-TN-14003ApprovedBiokine, Kyoto UniversityAPHEXDAUnited StatesHematopoietic stem cell transplantation (HSCT)Ayrmid Pharma Ltd2023-09-08Adenocarcinoma; Anemia, Aplastic; Anemia, Sickle Cell; Esophageal Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns